https://www.selleckchem.com/products/hdm201.html
Rufinamide is a tri-azole derivative drug that is structurally unrelated to any other anti-seizure drugs (ASD). It was developed first in 2004 and later was granted an orphan drug status in October 2004 and was first marketed in Europe in January 2007. It was approved by the US FDA on November 14, 2008, for the adjunctive treatment of seizures associated with Lennox Gastaut syndrome (LGS). Interestingly, it was the first anti-seizure medication to reach the US market, having a pediatric indication prior to approval for adults.A true cyst
Beğen
Yorum Yap
Paylaş
